Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
+1.72 (+2.26%)
4:48:19 PM EDT: $77.58 -0.13 (-0.17%)
Regulatory, Earnings Announcements

Merck & Co Says First-Line Treatment With Merck's KEYTRUDA Doubled Five-Year Survival Rate

Published: 09/21/2020 12:38 GMT
Merck & Co Inc (MRK) - Merck & Co Inc - Announced Five-year Survival Results From Pivotal Phase 3 Keynote-024 Trial.
Merck & Co Inc - First-line Treatment With Merck's Keytruda Doubled Five-year Survival Rate Versus Chemotherapy in Certain Patients.
Merck & Co Inc - Duration of Response With Keytruda As Monotherapy Was Nearly Five Times Longer Than Chemotherapy.
Merck & Co Inc - Keytruda Also Reduced Risk of Death by 38% Versus Chemotherapy.
Merck & Co Inc - No New Safety Signals for Keytruda Were Identified With Long-term Follow-up.
Merck & Co - 31.2% of Those Who Received Keytruda, 53.3% of Those Who Received Chemotherapy Experienced Grade 3-5 Treatment-related Adverse Events.
Merck & Co Inc - Among Patients Who Completed Two Years of Treatment With Keytruda, Grade 3-5 Traes Occurred in 15.4%.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.